News Catalent acquires gene therapy specialist Paragon for $1.2bn Drug delivery technology provider Catalent is to acquire gene therapy company Paragon for $1.2 billion.
News FDA rejects AbbVie’s continuous Parkinson’s therapy Delay could narrow the gap between AbbVie's product and a rival system from Mitsubishi Tanabe.
R&D Sponsored An inside guide to unlocking clinical research in the UK An inside guide to unlocking clinical research in the UK
